PDCD1 and melanoma: A recent example is the reformulation of MAGE-A3, NY-ESO-1, Tyrosinase and TPTE antigens given to melanoma patients as mRNA delivered by LNPs resulting in three (n = 25) patients experiencing partial response, seven (n = 25) stable disease, and six (n = 17) patients that received anti-PD-1 developing partial response [62].